PKO Investment Management Joint-Stock’s BioMarin Pharmaceuticals BMRN Stock Holding History

PKO Investment Management Joint-Stock’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,500	Closed	-$267K	–	223
2025 Q4	$267K	Sell	4,500 -4,500	-50%	-$245K	0.02%	205
2025 Q3	$487K	Hold	9,000	–	–	0.04%	178
2025 Q2	$495K	Hold	9,000	–	–	0.05%	156
2025 Q1	$636K	Sell	9,000 -3,000	-25%	-$202K	0.07%	151
2024 Q4	$789K	Hold	12,000	–	–	0.1%	120
2024 Q3	$843K	Buy	12,000 +6,000	+100%	+$502K	0.1%	119
2024 Q2	$494K	Sell	6,000 -3,000	-33%	-$250K	0.06%	145
2024 Q1	$790K	Buy	9,000 +3,000	+50%	+$269K	0.09%	126
2023 Q4	$579K	Hold	6,000	–	–	0.07%	129
2023 Q3	$531K	Sell	6,000 -3,000	-33%	-$267K	0.07%	121
2023 Q2	$780K	Buy	+9,000	New	+$847K	0.1%	117

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PKO Investment Management Joint-Stock's BMRN Position: Q1 2026 in Review

PKO Investment Management Joint-Stock sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 4,500 shares — an estimated $267K sold.

PKO Investment Management Joint-Stock first reported a position in BMRN in Q2 2023 and held it in 11 quarters. The position peaked at $843K in Q3 2024. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

PKO Investment Management Joint-Stock reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
PKO Investment Management Joint-Stock sold 4,500 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $267K.
PKO Investment Management Joint-Stock first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 11 quarters.
PKO Investment Management Joint-Stock's BioMarin Pharmaceuticals position peaked at $843K in Q3 2024.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on PKO Investment Management Joint-Stock's 13F filing for Q1 2026, filed 17 Apr 2026.